A six-month randomized, double-blind, placebo-controlled trial of the multi-ingredient supplement NOVOS Core reported a 2.6 percentage-point increase in flow-mediated dilation, reduced pulse wave velocity, and lower systolic blood pressure in generally healthy adults. The formula was tested as a whole, so no individual ingredient can be credited, and the trial was funded and supplied by the manufacturer. Endothelial responsiveness and arterial stiffness are among the more reliable vascular correlates of biological aging, which makes the magnitude of the reported effect notable despite the study's limitations.
Key Points
- Flow-mediated dilation rose 2.6 points over six months versus placebo
- Pulse wave velocity fell, indicating reduced arterial stiffness
- Manufacturer-funded trial; age imbalance and 30% attrition limit confidence
Longevity Analysis
Endothelial function and arterial stiffness track with cardiovascular events and decline predictably with age, making them among the few vascular measures worth monitoring serially rather than inferring from blood pressure alone. An intervention that moves flow-mediated dilation by nearly three percentage points would be clinically meaningful if the effect holds in independent, adequately powered trials with balanced groups. The more immediate lesson is practical: arteries respond to sustained daily input over months, and measuring the vessel's own signaling capacity gives a clearer read on vascular aging than a cuff reading does.
Original published by LifeSpan.io, by Arkadi Mazin.